Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.

[1]  S. Richman,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies , 2017, The Lancet Neurology.

[2]  V. Morra,et al.  CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients , 2017, Journal of Neuroimmunology.

[3]  P. Vermersch,et al.  CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy , 2016, Neurology.

[4]  D. Campagnolo,et al.  Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay , 2016, Journal of NeuroVirology.

[5]  V. Vullo,et al.  Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation , 2016, PloS one.

[6]  X. Montalban,et al.  PML risk stratification using anti-JCV antibody index and L-selectin , 2016, Multiple sclerosis.

[7]  L. Kappos,et al.  Natalizumab-induced POU2AF1/Spi-B upregulation , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[8]  A. Lugaresi,et al.  Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells , 2015, Journal of Neuroinflammation.

[9]  K. Reddy.  MicroRNA (miRNA) in cancer , 2015, Cancer Cell International.

[10]  H. Hartung,et al.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.

[11]  D. Campagnolo,et al.  Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.

[12]  P. Man,et al.  Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy. , 2014, Antiviral research.

[13]  L. Kappos,et al.  Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study , 2014, Neurology.

[14]  S. Baranzini,et al.  Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients , 2014, Multiple sclerosis.

[15]  E. Gamazon,et al.  The impact of microRNA expression on cellular proliferation , 2014, Human Genetics.

[16]  L. Kappos,et al.  MiR-126: a novel route for natalizumab action? , 2014, Multiple sclerosis.

[17]  P. Vermersch,et al.  l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients , 2013, Neurology.

[18]  P. Sørensen,et al.  Differential microRNA expression in blood in multiple sclerosis , 2013, Multiple sclerosis.

[19]  M. Subramanyam,et al.  A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  C. Louapre,et al.  Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab Therapy , 2013, Journal of Virology.

[21]  Yingke Li,et al.  MicroRNAs in the regulation of immune response against infections , 2013, Journal of Zhejiang University SCIENCE B.

[22]  E. Major,et al.  Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy , 2012, PLoS pathogens.

[23]  M. Subramanyam,et al.  An enhanced ELISA for detection of anti-JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification , 2012 .

[24]  E. Major,et al.  Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain , 2012, Clinical Microbiology Reviews.

[25]  L. Kappos,et al.  Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. , 2012, Clinical immunology.

[26]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[27]  A. Sandrock,et al.  Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002) , 2012 .

[28]  A. Sandrock,et al.  Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1 , 2011, Annals of neurology.

[29]  B. M. Keegan,et al.  Natalizumab for multiple sclerosis: a complicated treatment , 2011, The Lancet Neurology.

[30]  J. Carulli,et al.  Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients , 2011, The Journal of infectious diseases.

[31]  S. Bowden,et al.  Immunosuppression increases latent infection of brain by JC polyomavirus , 2011, Pathology.

[32]  L. Ngo,et al.  Role of CD4+ and CD8+ T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome , 2011, Journal of Virology.

[33]  E. Trinka,et al.  Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells , 2011, Journal of Neuroimmunology.

[34]  D. Clifford,et al.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease , 2010, Nature Reviews Neurology.

[35]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[36]  D. Clifford,et al.  Determinants of survival in progressive multifocal leukoencephalopathy , 2009, Neurology.

[37]  M. Lindsay,et al.  microRNAs and the immune response. , 2008, Trends in immunology.

[38]  L. Kappos,et al.  Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients , 2008, Journal of Neuroimmunology.

[39]  Peter T. Nelson,et al.  MicroRNAs (miRNAs) in Neurodegenerative Diseases , 2008, Brain pathology.

[40]  R. Ransohoff,et al.  Natalizumab for multiple sclerosis. , 2007, The New England journal of medicine.

[41]  H. Hartung,et al.  Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. , 2007, Archives of neurology.

[42]  R. Shivdasani.  MicroRNAs: regulators of gene expression and cell differentiation. , 2006, Blood.

[43]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[44]  B. Engelhardt,et al.  The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. , 2005, Trends in immunology.

[45]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[46]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[47]  P. Calabresi,et al.  Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale , 2005, Neurology.

[48]  M. Kuroda,et al.  A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. , 2004, Brain : a journal of neurology.

[49]  J. Christensen,et al.  Cytokine production by virus-specific CD8(+) T cells varies with activation state and localization, but not with TCR avidity. , 2004, The Journal of general virology.

[50]  N. Andrews,et al.  Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 , 2003, Journal of medical virology.

[51]  Subrata Ghosh.  Therapeutic value ofalpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab , 2003, Expert opinion on biological therapy.

[52]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[53]  S. Barry,et al.  Analysis of the α4β1 Integrin–Osteopontin Interaction , 2000 .

[54]  T. Mosmann,et al.  Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. , 1995, Immunity.

[55]  L. Burkly,et al.  Signaling by vascular cell adhesion molecule‐1 (VCAM‐1) through VLA‐4 promotes CD3‐dependent T cell proliferation , 1991, European journal of immunology.

[56]  F. Luscinskas,et al.  Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules , 1991, The Journal of experimental medicine.

[57]  Richard O. Hynes,et al.  Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor α 4 β 1 , 1990, Cell.

[58]  J.,et al.  The New England Journal of Medicine , 2012 .

[59]  W. Knowles.  Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). , 2006, Advances in experimental medicine and biology.

[60]  G. Lichtenstein.  Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease , 2006 .

[61]  D. Jeffery.  Natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[62]  S. Barry,et al.  Analysis of the alpha4beta1 integrin-osteopontin interaction. , 2000, Experimental cell research.

[63]  R. Hynes,et al.  Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. , 1990, Cell.

[64]  R. Ransohoff,et al.  CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients , 2016, Neurology.

[65]  L. Kappos,et al.  Natalizumab-induced POU 2 AF 1 / Spi-B upregulation A possible route for PML development , 2022 .